trials for patients with actionable mutations, & the importance of quality of life - onctalk 2022
Published 1 year ago • 49 plays • Length 4:12Download video MP4
Download video MP3
Similar videos
-
2:02
progression on pembrolizumab: patient without actionable mutations & low pd-l1 - lung cancer onctalk
-
4:29
studies in chemoimmunotherapy - lung cancer onctalk 2022
-
6:00
immunotherapy for patients with driver mutation - lung cancer video library
-
2:52
location of disease: can metastatic locations predict success of treatment? - onctalk 2022
-
2:49
q&a: are there ongoing trials for rare nsclc mutations? - targeted therapies in lung cancer 2023
-
5:42
osimertinib and the flaura trial
-
2:00
keynote 671: perioperative pembrolizumab for nsclc - onctalk lung 2023
-
3:24
clinical trials in patients with high risk or smm - blood cancer onctalk 2023
-
1:59:57
grace - global resource for advancing cancer education live stream
-
3:30
2020 peaprogram breast cancer series patients with brain metastases - prognosis & impact on survival
-
1:46
immunotherapy for patients with resectable nsclc & driver mutation-targeted therapies in lung cancer
-
2:43
curative strategies for patients with smoldering multiple myeloma - blood cancer onctalk 2023
-
1:55
how do i find clinical trials? - blood cancer onctalk
-
7:39
chemotherapy and immunotherapy for patients with kras mutations - asco lung review 2022
-
2:08
grace targeted therapies lung cancer 2021 - approved therapy for a cdkn2a secondary mutation?
-
3:37
hpv advances - identifying candidates for de-escalation
-
2:56
grace targeted therapies lung cancer 2021 - what trials are available for ntrk resistant mutation?
-
3:14
stereotactic body radiotherapy (sbrt) for oligoprogressive nsclc - onctalk lung 2023
-
2:22
aegean trial: perioperative durvalumab for nsclc - onctalk lung 2023